Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a global leader in diagnostic and therapeutic solutions, dedicated to advancing patient care across critical disease areas including cancer, cardiovascular conditions, and neurological disorders. The company's comprehensive portfolio features a range of innovative products designed to aid clinicians in precise diagnosis and effective treatment. Key offerings include DEFINITY, an ultrasound enhancing agent for echocardiography, and TechneLite, a technetium generator vital for nuclear medicine. Lantheus also provides specialized radiopharmaceuticals such as Xenon-133 for pulmonary assessment and Neurolite for stroke diagnosis. In the oncology space, the company is a significant player with PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer detection, and Automated Bone Scan Index, an AI-powered tool for quantifying prostate cancer burden. Beyond imaging, Lantheus offers therapeutic solutions like RELISTOR for opioid-induced constipation and is actively developing novel radiopharmaceutical therapies and diagnostic agents targeting various cancers and neurodegenerative diseases, including Alzheimer's. Strategic collaborations with industry partners further bolster its research and development pipeline, underscoring Lantheus' commitment to innovation and expanding its market reach in the rapidly evolving healthcare landscape.